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 ABSTRACT 
 
Background: Frailty is one of the most problematic expression of population 
ageing. It is a state of vulnerability and is associated with a greater risk for 
adverse outcomes such as falls, disability and death. Identifying early markers for 
the onset of this clinical syndrome is more than just a scientific challenge. One of 
the most important component of frailty is the sarcopenia, a progressive loss of 
skeletal muscle mass, strength, and power. Recent insight suggests that vitamin D 
may be important in preserving from muscle mass and, strength which are key 
components of frailty. Cognition and dementia have already been considered as 
components of frailty, but the role of frailty as a possible determinant of dementia 
has been poorly investigated. We examined the relationship  between serum 25-
hydroxyvitamin D (25OHD) levels and the presence of frailty  syndrome, and the 
association between vitamin D deficiency and the onset of frailty in a sample of 
older male and female adults. We also estimated the predictive role of frailty 
syndrome on incident dementia in the same population. 
Methods: This research is part of the Progetto Veneto Anziani (Pro.V.A), an 
Italian prospective population-based cohort study conduct in Italy between 1995 
and 2001 with follow up assessment at 4.4 years. A total of 1577 subjects (978 
women and 599 men) aged ≥ 65 years completed interviews, medical 
examinations and functional assessments, and provided blood samples. For the 
purpose of the second part of this study, 1181 partecipans (712 women and 469 
men) were studied, excluding subjects with alterations of MMSE. Serum 25OHD 
 levels were measured at the baseline and categorized into clinical groups: 25OHD 
deficient (<50 nmol/L), insufficient (≥50 to <75 nmol/L) and sufficient (≥75 
nmol/L). Frailty syndrome was defined using a modified measurement of 
Cardiovascular Health study criteria. Analyses were adjusted for relevant 
confounders including health status and physical performance.  
Results: Frailty was present at baseline in 457 (29%) subjects. The prevalence of 
frail syndrome was significantly higher among 25OHD-deficient participants 
compared to 25OHD-sufficient ones (43.4% vs 20.7%, p<.0001).  Compered to 
normal Vitamin D status, Vitamin D deficiency and vitamin D insufficient were 
independently associated to the likelihood of being frail, even adjusting for 
multiple potential confounders (OR: 1.657, 95% CI: 1.232-2.228; p<0.001 for the 
deficient group and OR: 1.392, 95% CI: 1.024-1.891; p<0.05). In a subsample of 
1129 non-frail participants, the 27% became frail at 4.4 years; nevertheless after 
adjusting for health and functional confounders, Vitamin D deficiency was no 
longer associated to the risk of the onset of frailty. Participants who developed 
dementia in follow-up were about 19% (228) of the sample. The subjects with 
frailty status were more likely to be dementia (OR: 1.87, 95% CI 1.02-3.30). 
Frailty syndrome was also associated with a greater risk of developing dementia 
(RR: 1.94, 95% CI: 1.42-2.64). 
Conclusion: Vitamin D deficiency is associated to frailty syndrome in elderly 
men and women, regardless of several confounding factors. By the way, vitamin 
D deficiency does not predict the onset of frailty, as well as other health condition. 
Frailty is a risk factor of dementia. 
 RIASSUNTO 
 
Introduzione: la fragilità è una delle maggiori problematiche della popolazione 
anziana. E’ uno stato di vulnerabilità ed è associata ad un aumento di diversi 
outcomes quali le cadute, la disabilità e la morte. Identificare precocemente 
marcatori dell’espressione clinica della sindrome è più di una sfida scientifica. 
Una delle più importanti componenti della fragilità è la sarcopenia, una 
progressiva perdita di massa, forza e potenza muscolare. Studi recenti 
suggeriscono che la vitamina D potrebbe avere un ruolo nel preservare massa e 
forza muscolari, componenti chiave della fragilità. Anche lo stato cognitivo e la 
demenza sono considerati componenti della fragilità, ma il ruolo della fragilità 
come possibile determinante della demenza è stato poco investigato. In questo 
studio è stata esaminata l’associazione tra la deficienza di vitamina D e la fragilità 
in un campione di uomini e donne anziani. Inoltre è stato esaminato il ruolo 
predittivo della fragilità sulla demenza nella stessa popolazione. 
Metodi: Questa ricerca fa parte del Progetto Veneto Anziani (Pro.V.A.), studio 
prospettivo di coorte della popolazione italiana, condotto in Italia tra il 1995 e il 
2001 con un follow-up a 4.4 anni. Un totale di 1577 soggetti (978 donne e 599 
uomini) di età ≥ 65 anni ha completato le interviste, gli esami medici, le 
valutazioni funzionali e ha fornito un campione di sangue. Nella seconda parte 
dello studio, sono stati valutati 1181 partecipanti (712 donne e 469 uomini), 
escludendo i soggetti con MMSE < 24. I livelli di vitamina D sono stati misurati 
al basale e categorizzati in sottogruppi: livelli deficienti (<50 nmol/L), 
 insufficienti (≥50 e <70 nmol/L) e sufficienti (≥75 nmol/L). La fragilità è stata 
definita usando i criteri modificati del Cardiovascular Health study. Le analisi 
sono state aggiustate per fattori confondenti, tra cui lo stato di salute e la 
performance fisica. 
Risultati: La fragilità al basale era presente in 457 (29%) soggetti. La prevalenza 
della fragilità era significativamente più alta tra i soggetti con deficienza di 
vitamina D rispetto ai soggetti con sufficienza (43.4% vs 20.7%, p<.0001). Se 
paragonate a livelli sufficienti di vitamina D, la deficienza e l’insufficienza di 
vitamina D erano indipendentemente associate ad una maggiore probabilità di 
essere fragili, anche dopo correzione per multipli potenziali fattori confondenti 
(OR: 1.657, 95% CI: 1.232-2.228; p<0.001 per la deficienza, e OR: 1.392, 95% 
CI: 1.024-1.891; p<0.05 per l’insufficienza di vitamina D). Dei 1129 partecipanti 
non fragili, il 27% diventa fragile a 4.4 anni; tuttavia dopo correzione per fattori 
confondenti, la deficienza di vitamina D non risulta più associata al rischio di 
sviluppare fragilità. I soggetti che sviluppano demenza nel follow-up era circa il 
19% (n=288) del campione. I soggetti fragili avevano maggiori probabilità di 
essere dementi (OR:1.87, 95% CI 1.02-3.30). Inoltre la fragilità risultava associata 
a un maggior rischio di sviluppare demenza (RR: 1.94, 95% CI 1.41-2.2.64), 
anche dopo correzione per fattori confondenti. 
Conclusioni: la deficienza di vitamina D risulta associata alla fragilità in uomini e 
donne anziani, indipendentemente da fattori confondenti. Tuttavia, la deficienza di 
vitamina D non predice il rischio di sviluppare fragilità, quando corretta per lo 
stato di salute. La fragilità risulta un fattore di rischio nello sviluppo di demenza. 
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INTRODUCTION 
 
Frailty has been described by Fried as a biological syndrome of decrease reserved 
and resistance to stressors, resulting from cumulative declines across multiple 
physiologic systems and causing vulnerability to adverse outcomes (Fried LP et 
al., 2001). It is characterized by weight loss, exhaustion, physical inactivity, 
reduced muscle strength, and slowed motor function (Fried LP et al., 2001). The 
presence of one or two of these criteria denotes pre-frailty. 
It independently predicts risks of adverse health outcomes including incident falls, 
fractures, disability and mortality. (Fried LP et al., 2001; Ensrud KE et al., 2007; 
Cawthon PM et al., 2007; Rockwood K et al. 2004).  
Frailty is common in older adults; in a recent meta-analysis, the prevalence of 
frailty in community-dwelling adults aged ≥ 65 years was found to be 10.7% 
(Collard et al. 2012). 
Identifying early markers for the onset of this clinical syndrome is more than just 
a scientific challenge. Preventing frailty may help slow progression of 
disablement process in older persons. 
One of the most important component of frailty is the sarcopenia, a progressive 
loss of skeletal muscle mass, strength, and power, measured by gait speed and grip 
strength in presence of a low muscle mass (Morley JE  et al., 2014; Cruz-Jentoft 
AJ et al., 2010). The phenotype of frailty including weakness and slowness (Fried 
LP et al., 2001). 
Recent evidence supports a role of vitamin D (25(OH)D) in physical performance 
and strength through direct effects on muscular function (Dawson-Hughes B , 
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2008; Ceglia L, 2008), as well as independently through its reported roles in 
cardiovascular diseases, diabetes mellitus, hypertension, pulmonary function, 
osteoarthritis (Holick MF , 2007) and cognitive disease (Toffanello ED et al., 
2014), condition that frequently lead to declines in physical performance and 
strength (Fried LP , 1997). Poor physical performance and muscle weakness have 
been associated with low 25OHD levels among older in cross-sectional studies 
(Bischoff HA et al. 1999; Zamboni M et al., 2002; Bischoff-Ferrari HA et al., 
2004; Houston DK et al., 2007; Annweiler C et al., 2010; Toffanello ED et al., 
2002). Low 25-hydroxyvitamin D (25(OH)D) levels are common in older adults 
(Lip P, 2001; Visser M et al., 2003) and have been linked to falls (Bischoff-Ferrari 
HA et al, 2006; Snijder MB et al., 2006), fractures (Bischoff-Ferrari et al., 2006), 
pain (Lips P, 2001; Visser M, et al, 2003; Bischoff-Ferrari et al., 2006), sarcopenia 
(Visser M et al., 2003), poor physical function (Gloth FM et al., 1995; Verhaar et 
al., 2000). The importance of vitamin D in maintaining calcium homeostasis is 
well known. Cholecalciferol is synthesized in the skin in response to ultraviolet 
light or is ingested through food (eg, fatty fish, eggs, fortified dairy products) and 
hydroxylatated into 25(OH)D in the liver. Older persons often have low 25(OH)D 
levels owing to age-related decrease efficiency of hydroxylation and reduced 
sunlight exposure (Lips P, 2001; Lips P, 2006). When 25(OH)D levels are low, 
active metabolite 1,25-dihydroxyvitamin D (1,25-(OH)2D) and calcium 
absorption decrease. The reduced serum calcium causes parathyroid hormone 
(PTH) levels to rise to stimulate 1,25(OH)2D production, resulting in increased 
bone turnover and hip fracture risk (Lips P, 2001; Lips P, 2006). Emerging 
research suggests that vitamin D affects muscle strength and function (Visser M et 
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al., 2003; Bischoff-Ferrari HA et al., 2004), both directly and indirectly through 
PTH regulation and inflammation (Lips P, 2001; Visser M et al., 2003; Houston 
DK, et al. 2007; Thomas MK et al., 1998; Puts MT et al., 2005(b)). 
There is evidence from several studies for a association between 25(OH)D levels 
and frailty (Puts MT et al., 2005(a); Shardall M et al., 2009; Ensrud KE et al., 
2010; Ensrud KE et al., 2011; Wilhelm-Leen ER et al., 2010; Hirani V et al., 
2013; Tajar A et al., 2013), nevertheless results from longitudinal studies on the 
association between 25(OH)D levels and incidents frailty are limited. Although 
low 25(OH)D levels were associated with incident frailty in some studies (Puts 
MT  et al., 2005; Wong YY et al., 2013), no significant relationship was found in 
others (Ensrud KE et al., 2011; Shardell M et al., 2012; Schottker B et al., 2014). 
Recent insight suggests that vitamin D may be also important in preserving 
cognitive function via different mechanisms. (Garcion E et al., 2002; Eyles DW et 
al., 2005; Annweiler C et al., 2011; Masoumi A et al., 2009; Annweiler C et al., 
2010 (2)). Toffanello et al. (Toffanello ED et al., 2014) in the same population of 
this study showed that to be an independent association between low 25OHD 
levels and cognitive decline in elderly individuals. If low levels of vitamin D are 
associated with frailty and cognitive decline, probably also the frailty will be 
associated with cognitive decline. 
In the ILSA, both lower cognition and greater depressive symptoms were cross-
sectionally associated with physical frailty (Solfrizzi V et al., 2012). Moreover, 
frail demented patients were at higher risk of all-cause mortality, but not of 
disability, over 3- and 7-years follow-up periods. In a recent population-based 
study, frailty status in older Mexican Americans cognitively unimpaired at 
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baseline was an indipendet predictor of cognitive decline over a 10-years period 
(Samper-Ternent R et al., 2008) furthermore, several studies have reported that 
physical frailty is significantly associated with low cognitive performances, 
including incidente of Alzheimer’s desease (AD) (Buchman AS et al., 2007), mild 
cognitive impairment (MCI) (Boyle PA et al., 2010) and AD pathology in older 
persons with and without dementia (Buchman AS et al., 2008).   
Cognition and dementia have already been considered as components of frailty, 
but the role of frailty as a possible determinant of dementia has been poorly 
investigated. Certain studies consider cognition to be a component of frailty. Most 
recent studies examined the influence of physical frailty on cognitive function 
impairment, whereas several others assume cognition to be a phychological risk 
factor for frailty (Panza F et al., 2011). Recently, an International Consensus 
Group has defined a “cognitive frailty” condition. (Kelaiditi E et al., 2013). As 
mentioned, the associations between frailty and cognitive function have been 
examined in literature, but not confirmed.  
Cross-sectional studies have found an association between frailty and poor 
cognitive function (Jacobs JM et al. 2011; Yassuda MS et al., 2012; Avila-Funes 
JA et al., 2011). Some studies even considered cognition to be a component of 
frailty (Sarkisian CA et al., 2008; Avila-Funes JA et al., 2008) which represents a 
clear risk factor for adverse health outcomes (e.g. physical disability or mortality) 
(Sakisian CA et al., 2008; Solfrizzi V et al., 2013). Longitudinal studies have 
found that physical frailty predicts future cognitive function decline and even the 
incidence of Alzheimer’s disease (Solfrizzi v, et al. 2013; Buchman AS et al., 
2007; Boyle PA et al., 2010; Mitnitski A et al., 2011). The rate of change in frailty 
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is also associated with cognitive decline (Buchman AS, et al, 2007). Frail older 
adults are less likely to show cognitive improvement or stabilization over time 
(Mitnitski A et al, 2011), as well as non-frail older people with poor cognition are 
more likely to became frail than those with good cognition (Raji MA et al., 2010). 
Frailty and cognitive function share related mechanisms. Risk factors commonly 
associated with frailty included gender (women), poor education, low 
socioeconomic status, marital status (never married, widow), disabling conditions, 
diabetes mellitus (especially if complicated), high comorbidity, depressive 
symptoms, fear of falling, social isolation, malnutrition, geriatric syndromes, 
retirement, and specific biomarkers (Woo J et al., 2005; Bischoff HA et al., 2006; 
Mhaolain AM et al., 2012). Factors related to poor cognitive function include age, 
gender (women), poor education, disabling conditions (especially in instrumental 
activities of daily living), diabetes, stroke, unhealthy behaviors, poor social 
support, and social isolation (Yen CH et al., 2010; Zunzunegui MV et al., 2003; 
Purser JL et al., 2005; Sabia S et al., 2009). 
Based on available literature, a possible relationship between cognitive function 
and frailty can be describe in multiple ways. First, cognitive impairment is a 
component of frailty. Second, cognitive impairment and frailty are characterized 
by synergistic actions in the development of negative health outcomes (e.g. 
mortality or disability). Third, cognitive impairment determines frailty. Fourth, 
frailty determines cognitive impairment.  
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 AIM OF THE STUDY 
 
The objectives of this study were to examine, at baseline, the relationship between 
serum 25-hydroxyvitamin D levels and the presence of frailty syndrome, and in 
the follow-up the association between vitamin D deficiency and the onset of 
frailty. 
In the subjects without alterations of MMSE, the objective was examine the 
possible role of frailty syndrome on incident dementia in a sample of older adults. 
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 METHODS 
 
Study population 
Data for  this analysis were drawn from the Progetto Veneto Anziani (Pro.V.A.), 
an observational cohort study on an Italian population of older  men and women 
(aged ≥ 65 years) living in two areas in the north-east of Italy.  
The baseline assessment started in 1995, finished in 1997, and was followed by 2 
in-person follow-up visits (at 5 and 7 years), with ongoing morbidity and 
mortality surveillance. All participants provided informed written consent to study 
participation and to morbidity surveillance. Participants were interviewed at their 
homes and were subsequently examined by physicians and nurses at the 2 study 
clinics using an extensive battery of clinical, instrumental, biochemical, and 
physical performance tests. The physician who performed the physical 
examination determined the disease status, integrating information from the 
interview, examination, use of medications, and medical records review.  
Briefly, the baseline Pro.V.A study population consisted of 3099 age- and sex-
stratified Caucasian community-dwelling participants (1854 women and 1245 
men) randomly selected between 1995-97 using a multistage stratification method 
designed to keep the male-to-female ratio at 2:3 and to oversample the oldest age 
group.  No exclusion criteria were used. Follow-up assessments were conducted 
after 4 years (mean [SD] follow-up, 4.4 [1.1] years). For the purposes of the 
present study, individuals without details of baseline serum 25(OH)D levels 
(n=272) or without one of the criteria to define frailty at baseline (n=826), were 
excluded, as were as subjects with severe renal failure (n=11) (glomerular 
filtration rate [GFR] <30), with primitive hyperparathyroidism (n=17), and 
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participants with leg and/or arm amputations (n=23), unable to walk and/or in 
wheelchairs (n=89). Of the remaining 1861 participants who have all baseline 
data, 181 subjects died during the follow-up, whereas 103 were alive but did not 
come back for the second visit. The final sample consisted of 1577 participants: 
599 men (mean [SD] age: 72.8 [7.0]) and 978 women (mean [SD] age: 74.6[6.7]). 
Compared with the sample as a whole, the excluded subjects (n=284) had the 
same distribution in male and female (63.0% vs 62.0% female and 37.0% vs 
38.0% male; Chi-Square test, p=0.7462). They were older (mean [SD] age: 79.4 
[7.3] vs 73.4 [6.4] years), and had lower serum vitamin D levels (mean [SD], 
67.0[20.2] vs 88.6 [53.8] nmol/L) (one-way ANOVA, p<.0001 for all 
comparisons). They were more likely than our study partecipants to have a 
diagnosis of depression (57.2% vs 29.2%; chi-square test, p<0.0001), dementia 
(61.6% vs 26.9%, chi-square test, p<0.0001), cardiovascular disease (36.6% vs 
15.2%, chi-square test, p<0.0001), neurologic disease (12.0% vs 1.8%, chi-square 
test, p<0.0001), diabetes (14.4% vs 7.9%, chi-square test, p=0.0003), and COPD 
(14.1% vs 7.3%, chi-square test, p=0.0001). Compared to participants, the 
excluded subjects were also more likely to be dependent in ADL (33.8% vs 
10.0%, chi-square, p<0.0001), and to be frailty (76.8% vs 29.0%, chi-square test, 
p<0.0001). 
For the purpose of the second part of this study, 1181 (469 men and 712 women) 
participants were studied, excluding subjects with MMSE ≥ 24 in baseline. 
Compared with the sample as a whole, the excluded subjects (n=396) had a same 
distribution in male and female (60.3% vs 59.1% female, and 39.7% vs 38.0% 
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male; Chi-Square test, p=0.7431) and they were older (mean[SD], 78.3[8.1] vs 
72.0 [5.6] years).  
 
Ethics approval 
The local Ethical Committees of Padua University and the Veneto Region's Local 
Health Units (ULSS) n.15 and n.18 approved the study protocol, and participants 
gave their written informed consent. 
 
Clinical and laboratory data 
Participants were examined at city hospitals by trained physicians and nurses both 
at the baseline and at the follow-up. Information on formal education, physical 
activity and smoking habits was collected during an in-person interview. Smoking 
habits were classified as “never/former” (for at least a year in the past) versus 
“current” smokers. Physical activities were grouped into two categories, i.e. 
outdoor activities (brisk walking, cycling, gardening, and fishing), and indoor 
activities (dancing, exercising at the gym). Participants were asked to report how 
many hours a week they had spent on each of the above-mentioned pastimes in 
the previous month. An activity was considered regular if it had been practiced for 
more than 1 hour a week during the previous month. Any diseases existing at the 
baseline were ascertained by board-certified physicians who examined all the 
clinical details, including medical history, self-reported symptoms, medical and 
hospital records, blood tests, and physical examination. Prior major diseases 
included any of the following: cardiovascular diseases (CVD: hypertension, 
congestive heart failure, angina and myocardial infarction, stroke, and peripheral 
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artery disease), diabetes, chronic obstructive pulmonary diseases (COPD), cancer, 
osteoarthritic diseases (including hand/knee/hip osteoarthritis, and hip fracture). 
Presence of depressive symptoms was assessed using the Geriatric Depression 
Scale, GDS (scores ≥11 were indicative of mood disorders) (Parmelee PA, Lawton 
MP, Katz IR. Psychological Assessment: A Journal of Consulting and Clinical 
Psychology 1989; Vol 1(4): 331-338). Disability was defined as the inability or 
need for assistance to perform one or more activities of daily living (ADL): 
bathing, dressing, eating, using the toilet, or transferring.  
Venous blood samples were obtained after an overnight fast, centrifuged and 
stored at -80°C. Routine biochemical tests were performed at city hospitals, and 
PTH and 25OHD tests at the Padua University laboratory. Serum 25OHD levels 
were measured by radioimmunoassay (RIA kit; DiaSorin). The intra- and inter-
assay coefficients of variation for 25OHD were 8.1% and 10.2%, respectively. 
Serum intact PTH levels were measured using a two-site immunoradiometric 
assay kit (N-tact PTHSP; DiaSorin), with intra- and inter-assay coefficients of 
variation for PTH of 3.0% and 5.5%, respectively. Serum creatinine was measured 
using a standard creatinine Jaffé method (Roche Diagnostics, Germany) and GFR 
was calculated with the MDRD formula (Levey AS et al. 2009).  
 
Frailty status  
Frailty status was defined using the following criteria, similar to those proposed 
by Fried and colleagues using data collected in the Cardiovascular Health Study 
(Fried LP, et al., 2001): 
• Weight loss: identified by weight loss > 5 kg in the past year; 
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• Exhaustion: identified by an answer of “no” to the question “Do you feel 
full of energy?” and GDS score ≥ 10;  
• Weakness: identified by inability to stand from a chair unaided, or without 
using the arms; 
• Slowness: defined as a mean gait speed < 0.8 m/s during 4 meters walks; 
• Low physical activity: identified by asking “Do you practice regular 
physical activity?”, defining physical activity as ≥ 4 hours/week in the 
previous month of the least moderate physical activity. 
Subjects with 3 or more components were considered to be frail. 
 
Cognitive function assessment  
Cognitive function was assessed at baseline and follow-up by administering the 
30-item Mini-Mental State Examination (MMSE) (Folstein MF et al., 1983; 
Figure 1), a validated neuropsychological tool for measuring global cognitive 
function with orientation, concentration, language, praxis and memory 
components designed to screen for cognitive impairment. When used repeatedly, 
the MMSE is also able to measure changes in cognitive status (Chea E et al., 
2011). MMSE scores range from 0 to 30; crude MMSE scores obtained in our 
sample were adjusted for age and formal education using coefficients proposed for 
the Italian population (Magni E et al., 1996). Adjusted scores lower than 24 
indicated a cognitive impairment (Malloy PF et al., 1997). A decline of 3 or more 
points at follow-up was define as a substantial cognitive decline (Bracco L et al, 
1998; Zhao Q et al., 2014).   
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Figure 1: Mini-mental state examination questionnaire  
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Statistical analysis 
Participants' baseline characteristics were summarized using means (± SD) for 
continuous variables and counts and percentage for categorical variables. Means 
and proportions were calculated in the sample as a whole, and by clinical group 
for serum 25OHD leveles, i.e. 25OHD deficient (<50 nmol/L); 25OHD 
insufficient (≥50 to <75 nmol/L); and 25OHD sufficient (≥75 nmol/L). (Holick 
MF, 2007).  
Differences in baseline characteristics by 25OHD levels were compared using chi-
square tests for categorical variables, analysis of variance for continuous variables 
with normal distributions, and the Kruskal-Wallis test for variables with skewed 
distributions.  
Multivariable logistic regression models were used to examine the association 
between baseline 25OHD levels and the odds of frailty in all participants.   
In secondary analyses, excluding participants with a baseline diagnosis of frailty, 
logistic regression models were applied to identify any association between 
25OHD levels and the onset of a frail condition at the follow-up. 
For all analyses, 25OHD status was coded as an indicator variable, considering 
the subjects with the highest serum vitamin levels (>75 nmol/L) as the reference 
group.  
In a basic adjusted model we checked for age in years, sex, body mass index 
(BMI; calculated as the weight in kg/height in meters squared), season of blood 
draw (autumn, winter, spring and summer) and smoking habits. In a second 
model, variables identified as potential confounders in studies on frailty or 
14 
 
 
25OHD levels were also included, i.e. depression, cardiovascular diseases, 
osteoarthrosis, neurological diseases, diabetes and COPD. PTH concentrations 
were also initially considered for inclusion in the analysis because they might act 
as intermediate factors of altered 25OHD levels, but they were subsequently 
removed from the models due to a high collinearity, as quantified by the variance 
inflation factor (VIF).  
In secondary analyses, excluding both partecipants with a baseline diagnosis of 
dementia and MMSE scores < 24, logistic regression models were applied to 
identify any association between frailty status and the onset of cognitive 
impairment (follow-up MMSE score < 24). In a basic adjusted model, we checked 
for age in years and sex. In a second model, variables identified as potential 
confounders were also included, i.e. smoking habit, MMSE, depression, 
cardiovascular diseases, diabetes, chronic obstructive pulmonary diseases, and 
osteoarthritis. 
All analyses were performed using the SAS rel. 9.13 (cary NC: SAS Institute). All 
statistical tests were two-tailed and statistical significance was assumed for p-
value <0.05. 
  
 
 
 
 
 
 
 
 
  
15 
 
 
 RESULTS 
 
The sample consisted of 1577 community-dwelling elderly individuals with a 
mean [SD] age of 73.4 [6.4] years. The mean [SD] baseline 25OHD serum level 
was 88.6 [56.0] nmol/L. Vitamin D deficiency (25OHD < 50 nmol/L) was 
identified in about 25% of the sample. At baseline about 29% of the participants 
was frail according to the revised criteria of the CHS, and about 43% of these frail 
subjects had a vitamin D deficiency. 
Table 1 shows the baseline characteristics of the sample, as a whole and by 
baseline vitamin D status. Participants who were 25OHD deficient were older 
than those with higher serum 25OHD levels, and they were more likely to be 
female. Subjects with lower 25OHD levels were more likely to be frail. Even 
controlling for age and sex, differences in baseline characteristics across 25OHD 
levels remain, for the exception of MMSE scores, dementia, and osteoarthrosys. 
In logistic regression models (Table 2), both vitamin D deficiency and 
insufficiency were independently associated to the likelihood of being frail. Even 
adjusting for multiple potential confounders, vitamin D deficient and insufficient 
partipants were at higher risk of being frail individuals compared to the sufficient 
subjects (OR 1.898, 95% CI 1.449-2.485 for the deficient group and OR 1.392, 
95% CI 1.024-1.891 for the insufficient, compared to the reference group).   
A total of 1129 subjects out of the 1577 participants were classified as non-frail at 
the baseline evaluation, and they represented  the sub-sample for secondary 
longitudinal analyses. Of these non-frail individuals a total of 304 (27%) match 
the frail criteria at the 4.4-year follow-up examinations, and low baseline vitamin 
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D levels (serum 25OHD <75 nmol/L) were observed in less than a health of them 
(47%). On logistic regression modeling of the relative risk of the onset of frail 
condition at follow-up, in individuals who did not match the frail criteria at the 
baseline evaluation (n= 1129) both vitamin D deficiency and insufficiency were 
not associated with a higher 4.4-year risk of becoming frail (Table 3).   
Table 4 shows the baseline characteristics of cognitively intact sample, as whole 
and by dementia at follow-up and not dementia at follow-up. Over a 4-4-years 
follow-up, 228 (about 19%) of 1181 older subject developed dementia. There 
were older than those did not developmend dementia and they were more likely to 
be female. At baseline, those subjects who developed dementia during the study 
period (n = 228), after age and sex adjusted, had lower level of education, lower 
MMSE score, more serious comorbidity, as well as frailty status, COPD, to be 
more depressed. The subjects with frailty status were more likely to be cognitively 
impaired, compared with the subjects without frailty (OR: 1.87; 95% CI: 1.02-
3.30). The incidence of dementia was higher in individuals with frailty syndrome 
than no-frail subjects (35.92% vs 18.02%). 
On logist regression modelling of the relative risk of the onset of dementia 
condition at follow-up, in individuals cognitively intact at the baseline evaluation 
(n = 1181), frailty syndrome was associated with a greater risk of developing 
dementia (RR: 1.94; 95% CI: 1.42-2.64) (Table 5). 
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Table 1: Baseline characteristics of the sample as a whole and by serum 
vitamin D levels. 
 
Serum 25OHD levels, nmol/L 
Characteristics 
ALL (1577: 
M:599 
F:978) 
<50 (n=389) 
(24.7%) 
≥50 and <75 
(n=359) 
(22.7%) 
≥75 (n=829) 
(52.6%) 
p Value 
Age and sex 
adjusted p 
values 
Age (y) 73.4±6.4 75.6±6.9 73.4±6.4 72.3±5.8 <0.0001 - 
Sex female, % 62.0 72.54 80.74 72.54 47.01 47.01 <0.0001 - 
BMI (m2/kg) 27.8±4.4 28.2±5.2 28.1±4.4 27.4±4.0 0.03 0.04 
Season of blood collection: 
Winter 
Autumn 
Spring 
Summer 
 
26.3 
30.9 
25.7 
17.1 
 
20.8 
25.6 
33.9 
19.7 
 
23.7 
36.6 
20.3 
19.3 
28.7 
30.8 
24.9 
15.5 <0.0001 <0.0001 
Dependency ADL, % 10.0 18.0 11.1 5.8 <0.0001 0.0001 
Regular physical activity, 
% 79.4 67.3 77.2 86.0 <0.0001 <0.0001 
Smokers, % 12.7 9.5 13.1 14.0 0.01 0.06 
Speed, m/s 0.70±0.20 0.64±0.21 0.71±0.17 0.77±0.17 <0.0001 <0.0001 
6-minWT, m 349.1±97.5 299.4±100.6 342.1±90.5 375.5±89.1 <0.0001 <0.0001 
GDS (score) 8.2±6.0 9.9±6.5 8.5±5.9 7.3±5.7 <0.0001 <0.0001 
Depression, % 29.2 39.8 28.9 24.4 <0.0001 0.001 
MMSE (score) 25.2±3.7 24.8±4.0 24.9±3.7 25.6±3.5 <0.0001 0.3 
Dementia, % 26.9 33.2 29.2 22.9 <0.0001 0.3 
CVD, % 15.2 18.0 12.3 15.2 0.37 0.34 
Neurological disease, % 1.8 3.6 1.96 0.97 <0.0001 0.03 
Diabetes, % 7.9 8.5 7.2 7.8 0.20 0,3 
COPD, % 7.3 8.0 6.7 7.2 0.17 0.002 
OA 33.3 37.5 36.9 29.3 0.01 0.82 
Frailty, % 29.0 43.4 32.6 20.7 <0.0001 <0.0001 
Biochemical       
25 OHD, nmol/L 88.6±56.0 33.5±11.2 61.5±7.2 126.1±52.2 - - 
Calcium, mg/dL 9.6±4.2 9.6±2.2 9.5±0.4 9.7±5.6 0.38 0.45 
PTH, 37.7±22.2 43.9±22.0 40.3±19.1 33.5±22.6 <0.0001 <0.0001 
Albumina, g/L 4.4±1.4 4.4±0.4 4.4±0.3 4.5±1.8 0.17 0.41 
GFR, mg/mL 70.4±18.0 67.9±18.7 69.0±17.1 73.5±17.1 <0.0001 0.53 
 
Abbreviations: BMI= body mass index; ADL=activities of daily living; 6-min WT= 6 minutes walking test; GDS= 
geriatric depression scale; MMSE= mini-mental state examination; CVD=cardiovascular diseases; COPD=chronic 
obstructive pulmonary disease; OA= osteoarthrosis; 25 OHD: hydroxyvitamin D3, PTH: parathyroid hormone; GFR: 
glomerular filtration rate. 
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Table 2: Cross-sectional association between 25-OHD3 levels and odds of 
greater frailty status. 
 
 
 
Table 3: Logistic regression model for the relative risk of frailty at 4.4 years 
in no frail participants, according to 25OHD serum levels.   
 
 
Odds ratio (95% CI) by serum 25OHD levels 
 25OHD <50 nmol/L 25OHD 50-74 25OHD ≥75 
Model 1a 
1.898 (1.449-2.485) 
p<0.0001 
1.436 (1.086-1.90) 
p= 0.01 
1.00 (referent) 
Model 2b 
1.657 (1.232-2.228) 
p<0.0008 
1.392 (1.024-1.891) 
p=0.03 
1.00 (referent) 
 
a: age, gender, BMI, season of blood draw, smoking. 
b: age, gender, BMI, season of blood draw, smoking, depression, cardiovascular diseases, osteoarthrosis, neurologic 
diseases, diabetes, COPD. 
Relative Risk (95% CI) by serum 25OHD levels 
 25OHD <50 nmol/L 25OHD 50-74 25OHD ≥75 
Model 1a 1.057 (0.737-1.517) 
p=0.76 
0.921 (0.650-1.3) 
p=0.64 
1.00 (referent) 
Model 2b 1.044 (0.716-1.522) 
p=0.82 
0.886 (0.613-1.28) 
p=0.51 
1.00 (referent) 
 
a: age, gender, BMI, season of blood draw, smoking. 
b: age, gender, BMI, season of blood draw, smoking, depression, cardiovascular diseases,  osteoarthrosis, neurologic 
diseases, diabetes, COPD. 
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Table 4: Baseline characteristics of the cognitively intact sample as a whole 
and by dementia at follow-up and not dementia at follow-up. 
 
 
 
 
Characteristics 
ALL 
(n:1181; 
M: 469 
F: 712) 
Subjects who did 
not developed 
dementia 
(n=953)  (80.7%) 
Subjects who 
developed dementia 
(n=228)  (19.3%) 
p Value 
Age and sex 
adjusted p 
values 
Age (y) 72.12±5.6 71.2±5.1 75.9±6.1 <0.0001  
Sex female, % 60.3  58.3  68.4 0.005  
BMI (m2/kg) 27.8±4.3 27.9±4.3 27.7±4.5  0.82 
Education (years) 6.22  6.38 4.01  0.015 
Independency in ADL, % 92.2 93.5 86.8  0.22 
Regular physical activity, %  82.1 82.8 79.4  0.78 
Smokers, % 14.6 15.5 11.0  0.80 
GDS (score) 7.6±5.8 7.2±5.8 9.1±5.9  0.0002 
Frail status (%) 25.1 22.5 36.0  0.05 
MMSE (score) 27.1±1.9 27.4±1.7 25.7±2.1  <0.0001 
CVD, % 14.25 12.7 20.7  0.1 
OA 30.9 28.9 39.1  0.41 
Diabetes, % 7.79 7.35 9.65  0.11 
COPD, % 7.8 6.41 13.6  0.0005 
Albumina, g/L 4.4±1.5 4.5±1.7 4.4±0.3  0.98 
 
Abbreviations: BMI= body mass index; ADL=activities of daily living; GDS= geriatric depression scale; MMSE= mini 
mental state examination; CVD=cardiovascular diseases; COPD=chronic obstructive pulmonary disease. 
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Table 5: Logistic regression model for the relative risk of dementia at 4.4 
years in frail participants. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Model Model 1a Model 2b Model 3c 
RR (95% CI) 
1.94 (CI 1.42-2.64) 
P<0.0001 
1.36 (1.12-1.91) 
P=0.05 
1.27 (1.11-1.80) 
P=0.05 
 
a: unadjusted model 
b: age, gender. 
c: age, gender, smoking, MMSE, depression, CVD, diabetes, COPD, AO. 
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 DISCUSSION 
 
Our study identified an association between vitamin D deficiency and frailty 
syndrome, regardless of several confounding factors.  
Previous cross-sectional studies including or limited to older women have 
inconsistently observed an independent association between lower 25(OH)D 
levels and frailty. The Longitudinal Aging Study Amsterdam (LASA) of 1321 
adults ≥65 years old (Puts MT et al., 2005) measured serum 25(OH)D using a 
competitive binding protein assay, defined frailty as the presence of three out of 
nine frailty indicators, and reported that the odds of being classified as frail (vs. 
non-frail) was 1.7-fold higher among those with levels between 10 and 20 ng/ml 
and 2.6-fold higher among those with levels <10 ng/ml, compared with that 
among the referent group (>20 ng/ml). The Women’s Heath and Aging Studies 
(Michelon E et al., 2006) measured serum 25(OH)D using a competitive binding 
protein assay, defined frailty using similar criteria to those used in the 
Cardiovascular heaith study index, and found an age-adjusted 1.7-fold higher odds 
of being classified as frail (vs. non-frail) among women with levels in the lowest 
quartile compared with that among women with levels in the upper three quartiles, 
but the association did not persist after further adjustment. Finally, the 
InCHIANTI study of older Italian men and women (Shardell M et al., 2009) 
measured serum 25(OH)D levels using a RIA, defined frailty with a modified 
CHS index, and reported that lower levels (<20 ng/ml) were associated with 
frailty in men, but not in women. While the InCHIANTI study found an 
independent association between lower 25(OH)D levels (<20 ng/ml) among 
women and the presence of only one of five individual frailty components (low 
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activity level), the current study using a similar frailty definition observed 
independent associations between lower 25(OH)D levels (<15 ng/ml or in the case 
of weakness <20 ng/ml) and the presence of each of five individual frailty 
dimensions (weakness, shrinking/sarcopenia, exhaustion, slowness, low activity 
level). 
Vitamin D deficiency may be associated with frailty through several biological 
pathways, including effects on bone, muscle, and immunity.  
Effects of vitamin D on bone health are well known (Lips P, 2006). Low 25(OH)D 
levels are associated, both directly and mediated through elevated PTH, with 
osteoporotic fractures and osteomalacia, a condition whereby new bone matrix is 
not properly mineralized (Lips P, 2001). These conditions, along with poor 
balance, (Zamboni M et al. 2002) may result in bodily pain (Mascarenhas R et al., 
2004) (eg, via progression of osteoarthritis) (McAlindo TE et al., 1996; Zhang Y 
et al., 2000) and fear of falling, which may contribute to sedentariness (Lips P, 
2001; Lips P, 2006; Tinetti ME et al., 1993).  
Additionally, low 25(OH)D may affect frailty via effects on muscle strength. 
Vitamin D receptors (VDRs) are located in skeletal muscle cells (Simpson RU et 
al., 1985), and low 25(OH)D may result in decreased muscle strength from both 
decreased muscle synthesis and altered contractile properties of muscle (Wassner 
SJ et al., 1983). Muscle protein synthesis is initiated by binding 1,25-(OH)2D to 
its nuclear receptor. The influence of 1,25-(OH)2D on calcium homeostasis is 
believed to influence contractile properties of muscle cells via both a VDR-
mediated genomic pathway and a nongenomic rapid mechanism (Boland R et al., 
1995). Thus, the association between low 25(OH)D and frailty may be explained 
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by associations of insufficient 25(OH)D with sarcopenia and muscle weakness 
because both are central to the frailty syndrome (Fried LP et al., 2001). Previous 
studies found associations of low 25(OH)D with low muscle strength (Visser M et 
al., 2003), poor balance (Zamboni M et al., 2002; Bischoff HA et al., 1999), and 
falls (Snijer MB et al., 2006). 
A third pathway through which low 25(OH)D may affect frailty stems from 
hypothesized anti-inflammatory properties of vitamin D (Lips P, 2006). The VDR 
has been identified on most immune system cells (Holick MF, 2005; van Etten et 
al., 2005). 
As well as the association between vitamin D deficiency and frailty, we evaluate 
the relationship of vitamin D status and risk of developing frailty. Previous large 
population-based cohort studies investigating the association between 25OHD 
levels and the risk to be frail reported conflicting results.  
Ensrud et al. among women classified as nonfrail (robust or intermediate) at 
baseline, founds some evidence of an independent association between lower 
25(OH)D levels (<20 ng/ml) at baseline and a higher odds of incident frailty or 
death at follow-up 4.5 years later (Ensrud KE et al., 2010). The LASA study (Puts 
MT et al., 2005) reported that among 885 nonfrail men and women at baseline, 
those with 25(OH)D levels <10 ng/ml, but not those with levels between 10–20 
ng/ml, had increased odds of being classified as frail (vs. nonfrail) at the 3-yr 
follow-up exam, compared with that among the referent group (>20 ng/ml). In 
contrast, an analysis of 463 women in the Women’s Health and Aging Study I 
(Semba RD et al., 2006) classified as nonfrail at baseline reported that the odds of 
becoming frail at follow-up did not differ between women in the lowest quartile of 
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25(OH)D as compared with that among women in the top three quartiles. In 
addition, among a sample of 1267 nonfrail men enrolled in the baseline 
examination of Osteoporotic Fractures in Men (MrOS) study, there was no 
association between lower baseline 25(OH)D level (<20 ng/ml) and odds of 
greater frailty status at a 4.6-year follow-up examination (Ensrud KE et al., 2011). 
In our study vitamin D deficiency does not predict the onset of frailty. 
Since there was no evidence to support an association between lower 25(OH)D 
levels and greater frailty status at follow-up, the observed cross-sectional 
association in this study may be due to the presence of residual confounding. 
Analyses were adjusted for multiple factors, but the possibility of residual 
confounding cannot be eliminated. 
Moreover, we had limited power to detect a longitudinal association because of 
smaller sample size. 
Another hypothesis is that in patients with hypovitamisis D, low levels of vitamin 
D could lead, over the years, conditions that become more important to involve 
frail syndrome, such as osteoporosis, fractures, sarcopenia and disability 
(Bischoff-Ferrari HA et al., 2006; Visser M et al., 2003). 
In the second part of the study, in our large cohort of Italian older individuals free 
of cognitive impairment at baseline, we found that frailty syndrome at baseline 
was a risk factor of developing dementia. 
Previous studies have reported  that frailty was associated with the level of 
cognition and dementia (Fried LP et al., 2001; Solfrizzi V et al., 2012; Panza F et 
al., 2011; Samper-Ternent R et al., 2008; Solfrizzi V et al., 2013). Two 
longitudinal populatio-based studies indicated that frailty syndrome was a 
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predictor of cognitive impairment in a 10-year follow-up (Samper-Ternent R et 
al., 2008), and that it was associated with the rate of cognitive decline in a 3-year 
follow-up period (Buchman AS et al., 2007). The Rush Memory and Aging 
Project also found that physical frailty increased the risk for MCI (Boyle PA et al., 
2010), altrough there is still controversy whether MCI is a separate syndrome or, 
indeed, a sign of early dementia (Boyle PA et al., 2010; Buchman AS et al., 2008).  
In the ILSA sample (Solfrizzi V et al., 2013), frailty syndrome was a predictor of 
overall dementia. Several of the individual components used to construct the 
measure of frailty in this study, including altered gait, slower movement, weight 
loss, and muscle weakness, have been associated with the development of 
dementia (Cronin-Stubbs D et al., 1997; Scarmeas N et al., 2005; Wilson RS et al., 
2003; Boyle PA et al., 2009). Furthemore, increased muscle strenght was 
associated with a decrease in the risk of incident Alzheimer’s disease and incident 
MCI and with a slower rate of decline in global cognitive function during a mean 
follow-up of 3.6 (boyle PA et al., 2009). 
Our finding suggested that factors associated with the development of frailty and 
its components were also associated with the development of dementia. For 
example, risk factors for cardiovascular disease (e.g. diabetes) have been related 
to both frailty (Afilalo J et al., 2009) and dementia (Bowler JV, 2005). In fact, 
several studies showed that comorbidities such as congestive heart failure, 
myocardial infarction, peripheral vascular disease, diabetes, and hypertention 
increase the risk for frailty (Afilalo J et al., 2009). 
Beyond the possible role of vascular risk factors and vascular-related diseases, 
there are several potential path-ways by which frailty could contribute to 
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cognitive decline; however, at present, the mechanisms underlying this suggested 
association remained unclear. One of these underlying pathogenetic factors may 
be inflammation. Increased markers of inflammation, such as C-reactive protein 
or proinflammatory interleukins, are common and have been implicated in frailty 
(Puts MT et al., 2005) (as already mentioned), cognitive impairment (Weaver JD 
et al., 2002), and dementia (Ma SL, 2005).  
In some forms of dementia, particularly AD, primary and supplementary motor 
cortices, the substantia nigra, and the striatum are often altered (Wolf DS et al., 
1999). Studies have shown that alterations in these areas of the brain are 
associated with modifications in the components of frailty such as weight loss and 
slow gait (Schneider JA et al., 2006, Buchman AS et al., 2006), suggesting the 
possibility that changes in neural systems that control motor function, metabolism, 
and fatigue may be present in frailty.  
One limitation of this part of our study is the small number of new cases of 
dementia. We also used the MMSE to diagnose dementia. Several studies report 
limitations of the MMSE in screening for dementia and cognitive impairment, 
specially in subcortical infarctions and small vessel disease, where it would not 
differentiate between focal and diffuse lesions. Furthermore, it would be 
insensitive to right-sided lesions (O’Sullivan M et al., 2005; Fure B et al., 2006). 
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CONCLUSION 
 
In conclusion, vitamin D deficiency at the baseline is independently associated 
with greater evidence to frailty syndrome in elderly; by the way, vitamin D 
deficiency were not predict the onset of frailty at 4.4 years, as well as other health 
condition. Future research is waranted to address the directionality of this 
association.  
Furthermore, frailty syndrome at baseline is associated with a greater risk of 
developing dementia. 
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